EUVIMEDEUVIMED entdecken
Crossref

Impact of peptide receptor radionuclide therapy ( PRRT ) on the quality of life in patients with neuroendocrine tumours

H Fernando iD, I Vito, N Santillan, G Gnanasegaran, A M Quigley, A Grossman iD, A R Hayes, D Mandair, C Toumpanakis, M Caplin, S Navalkissoor iD

Journal of Neuroendocrinology · 2026-06 · 38 (6)

DOI: 10.1111/jne.70201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 03.06.2026. Verfasst von H Fernando und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Royal Free London NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Quality of Life, Receptors, Peptide, Radiopharmaceuticals. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As peptide receptor radionuclide therapy (PRRT) maintains a key role in the treatment of neuroendocrine tumours (NETs), there is growing recognition of the importance of evaluating patient‐reported health related quality of life (HRQoL). To assess this impact meaningfully, validated instruments such as the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaires are invaluable. This study aims to evaluate the impact of PRRT on the HRQoL of patients with NETs, using generic cancer and GI‐NET‐specific EORTC questionnaires to provide a comprehensive understanding of how PRRT influences patient wellbeing beyond traditional clinical endpoints. Between 2015 and 2025, patients who underwent PRRT at Royal Free London Hospital, and consented to this study, completed GI.NET21 and C30 questionnaires before PRRT is administered at each cycle. Patients who completed the pre‐therapy questionnaire and at least one post‐PRRT questionnaire were included in this study. The response format of both questionnaires is a 4‐point Likert scale. Responses to the questionnaire were linearly transformed to a 0–100 scale using EORTC guidelines. A mean score difference >5 between any treatment cycles was considered clinically relevant, and p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsQuality of LifeReceptors, PeptideRadiopharmaceuticalsOctreotideRadioisotopesHumansFemaleMaleMiddle AgedAgedSurveys and QuestionnairesAdult

Stichwörter der Autor:innen

PRRTneuroendocrine tumoursquality of lifetherapy

Substanzen

Receptors, PeptideRadiopharmaceuticalsOctreotideRadioisotopes

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Royal Free London NHS Foundation Trust, London, UK.
  • Department of NET Unit, ENETS Centre of Excellence, Royal Free London NHS Foundation Trust, London, UK.

ORCID-Profile: H Fernando, A Grossman, S Navalkissoor

Zitieren

APA

Fernando, H., Vito, I., Santillan, N., Gnanasegaran, G., Quigley, A. M., Grossman, A., Hayes, A. R., Mandair, D., Toumpanakis, C., Caplin, M., & Navalkissoor, S. (2026). Impact of peptide receptor radionuclide therapy ( PRRT ) on the quality of life in patients with neuroendocrine tumours. Journal of Neuroendocrinology, 38(6). https://doi.org/10.1111/jne.70201

Vancouver

Fernando H, Vito I, Santillan N, Gnanasegaran G, Quigley AM, Grossman A, et al. Impact of peptide receptor radionuclide therapy ( PRRT ) on the quality of life in patients with neuroendocrine tumours. Journal of Neuroendocrinology. 2026;38(6). doi:10.1111/jne.70201

BibTeX
@article{Fernando2026,
  author = {Fernando, H and Vito, I and Santillan, N and Gnanasegaran, G and Quigley, A M and Grossman, A and Hayes, A R and Mandair, D and Toumpanakis, C and Caplin, M and Navalkissoor, S},
  title = {Impact of peptide receptor radionuclide therapy ( PRRT ) on the quality of life in patients with neuroendocrine tumours},
  journal = {Journal of Neuroendocrinology},
  year = {2026},
  volume = {38},
  number = {6},
  doi = {10.1111/jne.70201}
}
Kostenlos starten →